The Pharmacy Times® Pharmacy Technician Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to specialty pharmacists.
May 1st 2025
The Inflation Reduction Act's (IRAs) drug negotiation provisions will fundamentally reshape Medicare drug pricing, provider reimbursement, and healthcare delivery dynamics across Part B and commercial markets, according to panelists at Asembia’s AXS25 Summit.
Eligibility for Genetic Testing in Lynch Syndrome Expands With New NCCN Guidelines
March 21st 2014More patients with Lynch syndrome will be eligible for genetic testing with availability of a new, more sensitive assay from Myriad Genetics and support for wider use of the test through guidelines issued by the National Comprehensive Cancer Network.
Read More
Predicting Cardiotoxicity Before it Happens in Patients with Breast Cancer
March 18th 2014Using a very high sensitivity assay analyzing changes in levels of MPO and troponin I before, and 3 months after starting a chemotherapy regimen, investigators were able to predict 46.5% of cases of chemotherapy-associated cardiotoxicity before they occurred.
Read More
The AASLD/IDSA Guideline for Treatment of Hepatitis C Virus: An In-Depth Guide
March 13th 2014Of the 3 to 4 million Americans with chronic HCV infection, only 13% to 18% have received treatment. Understanding the current guidelines in HCV treatment and understanding the current role of direct-acting antiviral agents is an important priority for pharmacists.
Read More
Isotretinoin and Inflammatory Bowel Disease: Is There a Link?
February 25th 2014Isotretinoin, a treatment for severe acne, has been linked to inflammatory bowel disease (IBD) in some case reports and 1 study. To investigate whether isotretinoin can induce IBD, French researchers conducted a 2-year nationwide registry study.
Read More
Multiple Myeloma and Type 2 Diabetes Mellitus: A Clinical Challenge
February 20th 2014Poorly controlled type 2 diabetes mellitus in patients with multiple myeloma (MM) may increase the risk of adverse cardiovascular outcomes, kidney damage, and peripheral neuropathy. Considering the effect of medications to treat MM on blood glucose control may be an important part of choosing a treatment regimen for some patients.
Read More
Uncloaking Tumor Cells With Programmed-Death Receptor-1 Inhibitors
February 14th 2014Scientists are using monoclonal antibodies to help the body fight off tumors in the same way that the body fights off infections. Monoclonal antibodies that target the interaction of programmed-death receptor-1 (PD-1) on T cells and its ligand (PD-L1) on tumor cells. Merck's MK-3475 prevents the interaction of PD-1 and PD-L1, thereby inhibiting a mechanism by which some tumors avoid immune detection.
Read More